Moreover, NAFLD patients show a reduced insulin-mediated inhibition of lipolysis [20–22], that results in increased flux of free fatty acids (FFAs) to the liver and in a blunted inhibition of fatty acid oxidation. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.